Company / Revenue
Tarsus Pharmaceuticals, Inc. Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$451.4M
FY2025
5-year range
$17.4M / $451.4M
FY2021-FY2025
Trend
+146.7%
vs FY2024
Sector context
#68 of 155
Health Care
What the data says
At $451M, Tarsus Pharmaceuticals, Inc.'s revenue ranks #68 of 155 in the Health Care sector. Improved from $17M to $451M over the past 2 years.
Based on SEC 10-K filings.
$451M in FY2025 with a 3-year CAGR of +99.3%.
Improved from $17M to $451M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +99.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#68 of 155 in Health CareTop 44% of 155This company $451.4M Sector average $4.5B
▼
-89.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +99.3%, indicating consistent growth.
- In FY2025, revenue increased 146.7% year-over-year.
- Ranks #68 out of 155 companies in the Health Care sector.
- Lowest revenue in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $451.4M | +146.7% |
| FY2024 | $183.0M | +948.6% |
| FY2023 | $17.4M | -69.4% |
| FY2022 | $57.0M | +0.0% |
| FY2021 | $57.0M | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026